Network pharmacology-based investigation and experimental validation of the mechanism of metformin in the treatment of acute myeloid leukemia
Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid leukemia. However, the detailed mechanisms by which metformin influences acute myeloid leukemia remain unrevealed. Employing a synergistic approach of...
Saved in:
Published in | European journal of medical research Vol. 29; no. 1; pp. 475 - 12 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
30.09.2024
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid leukemia. However, the detailed mechanisms by which metformin influences acute myeloid leukemia remain unrevealed. Employing a synergistic approach of network pharmacology and experimental validation, this study systematically identifies and analyzes potential metformin targets and AML-related genes. These findings are then cross-referenced with biomedical databases to construct a target-gene network, providing insights into metformin's pharmacodynamics in AML treatment. Protein-Protein Interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses are utilized. Results show metformin's effectiveness in inhibiting AML cell proliferation and inducing apoptosis through the AKT/HIF1A/PDK1 signaling pathway. This research provides insights into metformin's clinical application in AML treatment. |
---|---|
AbstractList | Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid leukemia. However, the detailed mechanisms by which metformin influences acute myeloid leukemia remain unrevealed. Employing a synergistic approach of network pharmacology and experimental validation, this study systematically identifies and analyzes potential metformin targets and AML-related genes. These findings are then cross-referenced with biomedical databases to construct a target-gene network, providing insights into metformin's pharmacodynamics in AML treatment. Protein-Protein Interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses are utilized. Results show metformin's effectiveness in inhibiting AML cell proliferation and inducing apoptosis through the AKT/HIF1A/PDK1 signaling pathway. This research provides insights into metformin's clinical application in AML treatment.Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid leukemia. However, the detailed mechanisms by which metformin influences acute myeloid leukemia remain unrevealed. Employing a synergistic approach of network pharmacology and experimental validation, this study systematically identifies and analyzes potential metformin targets and AML-related genes. These findings are then cross-referenced with biomedical databases to construct a target-gene network, providing insights into metformin's pharmacodynamics in AML treatment. Protein-Protein Interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses are utilized. Results show metformin's effectiveness in inhibiting AML cell proliferation and inducing apoptosis through the AKT/HIF1A/PDK1 signaling pathway. This research provides insights into metformin's clinical application in AML treatment. Abstract Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid leukemia. However, the detailed mechanisms by which metformin influences acute myeloid leukemia remain unrevealed. Employing a synergistic approach of network pharmacology and experimental validation, this study systematically identifies and analyzes potential metformin targets and AML-related genes. These findings are then cross-referenced with biomedical databases to construct a target-gene network, providing insights into metformin's pharmacodynamics in AML treatment. Protein–Protein Interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses are utilized. Results show metformin's effectiveness in inhibiting AML cell proliferation and inducing apoptosis through the AKT/HIF1A/PDK1 signaling pathway. This research provides insights into metformin's clinical application in AML treatment. Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid leukemia. However, the detailed mechanisms by which metformin influences acute myeloid leukemia remain unrevealed. Employing a synergistic approach of network pharmacology and experimental validation, this study systematically identifies and analyzes potential metformin targets and AML-related genes. These findings are then cross-referenced with biomedical databases to construct a target-gene network, providing insights into metformin's pharmacodynamics in AML treatment. Protein-Protein Interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses are utilized. Results show metformin's effectiveness in inhibiting AML cell proliferation and inducing apoptosis through the AKT/HIF1A/PDK1 signaling pathway. This research provides insights into metformin's clinical application in AML treatment. Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid leukemia. However, the detailed mechanisms by which metformin influences acute myeloid leukemia remain unrevealed. Employing a synergistic approach of network pharmacology and experimental validation, this study systematically identifies and analyzes potential metformin targets and AML-related genes. These findings are then cross-referenced with biomedical databases to construct a target-gene network, providing insights into metformin's pharmacodynamics in AML treatment. Protein-Protein Interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses are utilized. Results show metformin's effectiveness in inhibiting AML cell proliferation and inducing apoptosis through the AKT/HIF1A/PDK1 signaling pathway. This research provides insights into metformin's clinical application in AML treatment. Keywords: Network pharmacology, Metformin, AML, Apoptosis, HIF1A |
ArticleNumber | 475 |
Audience | Academic |
Author | Yang, Zhuofan Tang, Xiaowen Xu, Mingming Liu, Shaoyu Li, Yangzi Wu, Depei |
Author_xml | – sequence: 1 givenname: Shaoyu surname: Liu fullname: Liu, Shaoyu – sequence: 2 givenname: Mingming surname: Xu fullname: Xu, Mingming – sequence: 3 givenname: Zhuofan surname: Yang fullname: Yang, Zhuofan – sequence: 4 givenname: Yangzi surname: Li fullname: Li, Yangzi – sequence: 5 givenname: Depei surname: Wu fullname: Wu, Depei – sequence: 6 givenname: Xiaowen surname: Tang fullname: Tang, Xiaowen |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39343915$$D View this record in MEDLINE/PubMed |
BookMark | eNptkt1u1DAQhSNUREvpC3CBIiEhblLs2Pm7QlXFT6UKbkDizprY4123TrzYzsL2HXhnnE2puhKKolgz35z42Od5djS6EbPsJSXnlLb1u8AJIbQgJU8vKcvi7kl2UhLeFE3Lfhw9Wh9nZyHcJJrUZd103bPsmHWMs45WJ9mfLxh_OX-bb9bgB5DOutWu6CGgys24xRDNCqJxYw6jyvH3Br0ZcIxg8y1Yo5ae03lcYz6gXMNowjAXBoza-cGMSWffjR4hzrNzF-QU08AOrTMqtzjd4mDgRfZUgw14dv89zb5__PDt8nNx_fXT1eXFdSEr2saiJFBD2TKlUZeMdZpBi5xLVFRxxLLSjWy5Yih7BZRUDae6gapu-lbLhvfsNLtadJWDG7FJlsDvhAMj9gXnVwJ8NNKigKbnnNYKmeo5aOyaSgNCVdac97pXSev9orWZ-gGVTAY92APRw85o1mLltoJSzkld1Unh7b2Cdz-ndORiMEGitTCim4JglNJ0xenPCX29oCtIezOjdklSzri4aJPTtkv7StT5f6j0qHTIMuVIm1Q_GHjzaGCNYOM6ODvNlxsOwVePzT64_BeoBJQLIL0LwaN-QCgRc3DFElyRgiv2wRV37C9nT-PX |
Cites_doi | 10.1016/j.tips.2021.11.004 10.1001/jama.2019.3805 10.3390/ijms21082907 10.1016/j.gene.2019.02.076 10.3390/biom13020250 10.3389/fphar.2022.952677 10.1186/s13045-021-01062-w 10.1136/bmj.n2026 10.1186/s12943-023-01827-6 10.1016/j.metabol.2022.155223 10.1080/10428194.2017.1330956 10.1186/s13045-023-01424-6 10.1093/nar/gkz382 10.1016/j.redox.2019.101197 10.1016/j.gene.2017.06.035 10.3390/curroncol29090491 10.1016/j.gene.2021.145796 10.1002/ajh.26822 10.1038/nchembio.118 10.1111/cbdd.13860 10.1093/nar/gkw937 10.3389/fendo.2020.00191 |
ContentType | Journal Article |
Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. The Author(s) 2024 2024 |
Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: The Author(s) 2024 2024 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.1186/s40001-024-02022-z |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2047-783X |
EndPage | 12 |
ExternalDocumentID | oai_doaj_org_article_a7b4416de3db4afe975faea52644bfbd PMC11440656 A810589264 39343915 10_1186_s40001_024_02022_z |
Genre | Journal Article |
GrantInformation_xml | – fundername: Frontier Clinical Technical Project of Suzhou Science and Technology plan grantid: (SKY2022001) – fundername: the Priority Academic Program Development of Jiangsu Higher Education Institutions grantid: (PAPD) – fundername: Bethune Charitable Foundation grantid: (BCF-IBW-XY-20220930-13) – fundername: Natural Science Foundation of Jiangsu Province grantid: (BK20201169) – fundername: National Natural Science Foundation of China grantid: 81873443 – fundername: Suzhou diagnosis and treatment project of Clinical Key Diseases grantid: (LCZX202201) – fundername: The Key Science Research Project of Jiangsu Commission of Health grantid: (K2019022) – fundername: National Natural Science Foundation of China grantid: 82070162 – fundername: Translational Research Grant of NCRCH grantid: (2020ZKZC04) |
GroupedDBID | --- 0R~ 4.4 53G 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABUWG ACGFS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION DIK EBD EBLON EBS EMOBN F5P FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 UKHRP CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c518t-20a6a283dfef2339f3a8e44ced1d4ee25f7c84d3ecbda105741f7a567b8fc74b3 |
IEDL.DBID | M48 |
ISSN | 2047-783X 0949-2321 |
IngestDate | Wed Aug 27 01:16:12 EDT 2025 Thu Aug 21 18:31:07 EDT 2025 Fri Jul 11 15:57:36 EDT 2025 Tue Jun 17 22:03:19 EDT 2025 Tue Jun 10 20:58:21 EDT 2025 Thu May 22 21:25:17 EDT 2025 Mon Jul 21 05:40:29 EDT 2025 Tue Jul 01 02:25:22 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | AML Network pharmacology Metformin HIF1A Apoptosis |
Language | English |
License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c518t-20a6a283dfef2339f3a8e44ced1d4ee25f7c84d3ecbda105741f7a567b8fc74b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s40001-024-02022-z |
PMID | 39343915 |
PQID | 3111202975 |
PQPubID | 23479 |
PageCount | 12 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_a7b4416de3db4afe975faea52644bfbd pubmedcentral_primary_oai_pubmedcentral_nih_gov_11440656 proquest_miscellaneous_3111202975 gale_infotracmisc_A810589264 gale_infotracacademiconefile_A810589264 gale_healthsolutions_A810589264 pubmed_primary_39343915 crossref_primary_10_1186_s40001_024_02022_z |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-09-30 |
PublicationDateYYYYMMDD | 2024-09-30 |
PublicationDate_xml | – month: 09 year: 2024 text: 2024-09-30 day: 30 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | European journal of medical research |
PublicationTitleAlternate | Eur J Med Res |
PublicationYear | 2024 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | Z Huang (2022_CR10) 2022 JA Webster (2022_CR2) 2018; 59 LF Newell (2022_CR5) 2021; 375 KK Gundapaneni (2022_CR23) 2017; 5 RJ Stubbins (2022_CR3) 2022; 29 P Yadav (2022_CR22) 2021; 98 S Shimony (2022_CR1) 2023; 98 AL Hopkins (2022_CR17) 2008; 4 RS Bhansali (2022_CR15) 2023; 16 C Nogales (2022_CR9) 2022; 43 J Flory (2022_CR6) 2019; 321 M Rashid (2022_CR20) 2021; 798 A Daina (2022_CR11) 2019; 47 A Glaviano (2022_CR13) 2023; 22 T Liu (2022_CR21) 2019; 25 E Minet (2022_CR14) 2000; 5 S Noorolyai (2022_CR19) 2019; 25 CR Triggle (2022_CR16) 2022; 133 YZ Fang (2022_CR8) 2023; 13 I Nepstad (2022_CR18) 2020; 21 H Liu (2022_CR4) 2021; 14 Z Lv (2022_CR7) 2020; 11 D Szklarczyk (2022_CR12) 2017; 45 |
References_xml | – volume: 43 start-page: 136 issue: 2 year: 2022 ident: 2022_CR9 publication-title: Trends Pharmacol Sci. doi: 10.1016/j.tips.2021.11.004 – volume: 321 start-page: 1926 issue: 19 year: 2019 ident: 2022_CR6 publication-title: JAMA doi: 10.1001/jama.2019.3805 – volume: 21 start-page: 2907 issue: 8 year: 2020 ident: 2022_CR18 publication-title: Int J Mol Sci doi: 10.3390/ijms21082907 – volume: 25 start-page: 120 issue: 698 year: 2019 ident: 2022_CR19 publication-title: Gene doi: 10.1016/j.gene.2019.02.076 – volume: 13 start-page: 250 year: 2023 ident: 2022_CR8 publication-title: Biomolecules doi: 10.3390/biom13020250 – year: 2022 ident: 2022_CR10 publication-title: Front Pharmacol. doi: 10.3389/fphar.2022.952677 – volume: 14 start-page: 49 year: 2021 ident: 2022_CR4 publication-title: J Hematol Oncol. doi: 10.1186/s13045-021-01062-w – volume: 375 year: 2021 ident: 2022_CR5 publication-title: BMJ doi: 10.1136/bmj.n2026 – volume: 22 start-page: 138 issue: 1 year: 2023 ident: 2022_CR13 publication-title: Mol Cancer doi: 10.1186/s12943-023-01827-6 – volume: 133 year: 2022 ident: 2022_CR16 publication-title: Metabolism doi: 10.1016/j.metabol.2022.155223 – volume: 59 start-page: 274 issue: 2 year: 2018 ident: 2022_CR2 publication-title: Leuk Lymphoma. doi: 10.1080/10428194.2017.1330956 – volume: 16 start-page: 29 issue: 1 year: 2023 ident: 2022_CR15 publication-title: J Hematol Oncol doi: 10.1186/s13045-023-01424-6 – volume: 47 start-page: W357 issue: W1 year: 2019 ident: 2022_CR11 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkz382 – volume: 25 year: 2019 ident: 2022_CR21 publication-title: Redox Biol doi: 10.1016/j.redox.2019.101197 – volume: 5 start-page: 253 issue: 3 year: 2000 ident: 2022_CR14 publication-title: Int J Mol Med – volume: 5 start-page: 278 issue: 627 year: 2017 ident: 2022_CR23 publication-title: Gene doi: 10.1016/j.gene.2017.06.035 – volume: 29 start-page: 6245 issue: 9 year: 2022 ident: 2022_CR3 publication-title: Curr Oncol doi: 10.3390/curroncol29090491 – volume: 798 year: 2021 ident: 2022_CR20 publication-title: Gene doi: 10.1016/j.gene.2021.145796 – volume: 98 start-page: 502 year: 2023 ident: 2022_CR1 publication-title: Am J Hematol doi: 10.1002/ajh.26822 – volume: 4 start-page: 682 issue: 11 year: 2008 ident: 2022_CR17 publication-title: Nat Chem Biol doi: 10.1038/nchembio.118 – volume: 98 start-page: 144 issue: 1 year: 2021 ident: 2022_CR22 publication-title: Chem Biol Drug Des doi: 10.1111/cbdd.13860 – volume: 45 start-page: D362 issue: D1 year: 2017 ident: 2022_CR12 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkw937 – volume: 11 start-page: 191 year: 2020 ident: 2022_CR7 publication-title: Front Endocrinol doi: 10.3389/fendo.2020.00191 |
SSID | ssj0000626799 |
Score | 2.36626 |
Snippet | Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid leukemia.... Abstract Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 475 |
SubjectTerms | AML Apoptosis Apoptosis - drug effects Cancer Care and treatment Cell Proliferation - drug effects Diabetes therapy Drug therapy Gene Regulatory Networks - drug effects Genes Genomes Genomics HIF1A Humans Hypoxia-Inducible Factor 1, alpha Subunit - genetics Hypoxia-Inducible Factor 1, alpha Subunit - metabolism Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - metabolism Leukemia, Myeloid, Acute - pathology Metformin Metformin - pharmacology Metformin - therapeutic use Network pharmacology Network Pharmacology - methods Pharmacology Protein Interaction Maps - drug effects Protein-protein interactions Proto-Oncogene Proteins c-akt - metabolism Signal Transduction - drug effects Type 2 diabetes |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k2gBSMhcUBRSew4ybEgqgqpPVGpN8uPsYjoJlU3e2j_A_-5M3Z2m4gDFw57yUyitWfG30SZ-Yaxj0GUQDxleXAgcymDza0qmlwgvAjwra8U9Q6fnqmTc_njorqYjfqimrBED5w27tDUFhFbeRDeShOgratgwFQE5DZYT6cvYt7sZSqdwaWq23bbJdOow7X8EquHSok_KmG_XSBRJOz_-1ie4dKyZnIGQsdP2OMpe-RH6V8_ZQ-gf8Yenk7fx5-zP2epqptf3TNS3-SEVJ5394waQ89N7_mc3Z-jx3VpvhIfAse0kK-AuoK79YourGCk9Lbr8TlRuqtQJ6lxmxFvuIHLofP8Eja_YdWZF-z8-PvPbyf5NHAhd1XRjBgxRhnMN3yAUArRBmEakNKBL7wEKKtQu0Z6Ac56QwOCZRFqU6naNsHV0oqXbK8fenjNuAVMpkKL-Z0RMgjVOgMVEPmirIMqy4x93m6-vkq8Gjq-jzRKJ1NpNJWOptK3GftK9tlpEid2vICeoidP0f_ylIy9J-vq1GC6i2x91BQ0WxHVMvYpalBso5GdmVoUcEnEkrXQ3F9oYky6hfjD1oM0iaiQrYdhs9YCsaWkgWFVxl4lj9qtSrSC-qBR0ix8bbHspaTvfkVK8IK-0WNq_uZ_bNRb9qiMcUJVMftsb7zewAGmXqN9F6PsDqMVMVw priority: 102 providerName: Directory of Open Access Journals |
Title | Network pharmacology-based investigation and experimental validation of the mechanism of metformin in the treatment of acute myeloid leukemia |
URI | https://www.ncbi.nlm.nih.gov/pubmed/39343915 https://www.proquest.com/docview/3111202975 https://pubmed.ncbi.nlm.nih.gov/PMC11440656 https://doaj.org/article/a7b4416de3db4afe975faea52644bfbd |
Volume | 29 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3di9NAEF_uA8QX8dvqWSMIPkjUZDfZ5EGkJ3cchRZRC31bdrOzGmyTsx9g73_wf3Zmk_YaPPAhBDKTwGZmMr8kM79h7JXjMRBPWegKEKEQzoQmjbKQY3rhYHObpNQ7PBqnFxMxnCbTA7Ydd9TewOWNr3Y0T2qymL39_WvzEQP-gw_4LH23FO99YVAscKPq9KtDdoyZSdJEg1EL95snc5zKvKHfE3mIYCLa9tHceJlOrvKU_v8-uPcyV7eqci9Nnd9ld1p8GQwah7jHDqC6z26N2j_oD9ifcVP3HVxec1ZvQsplNiivOTfqKtCVDfb5_wP0ybKZwBTULkDgGMyB-obL5ZwOzGFFALis8DpeuqthJ6ku1is8YQOzurTBDNY_YV7qh2xyfvbt00XYjmQIiyTKVhhTOtWISKwDF3OeO64zEKIAG1kBECdOFpmwHApjNY0QFpGTOkmlyVwhheGP2FFVV_CEBQYQbrkcEaDmwvE0LzQkQPSMQro0jnvszfbmq8uGeUP5N5YsVY2pFJpKeVOpqx47JfvsNIk12x-oF99VG4RKS4PoL7XArRHaQS4Tp0EnBAqNM7bHXpB1VdOCuot9Ncgimr6Iaj322muQP6KRC902MeCSiEero3nS0cSoLTril1sPUiSiUrcK6vVSccw-MY0US3rsceNRu1XxnFOnNEqyjq91lt2VVOUPTxoe0V98BO9P_7vGZ-x27IOAimJO2NFqsYbniLxWps8O5VT22fFgMPw6xP3p2fjzl77_jtH3ofYXmYQyQA |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Network+pharmacology-based+investigation+and+experimental+validation+of+the+mechanism+of+metformin+in+the+treatment+of+acute+myeloid+leukemia&rft.jtitle=European+journal+of+medical+research&rft.au=Yang%2C+Zhuofan&rft.au=Tang%2C+Xiaowen&rft.au=Xu%2C+Mingming&rft.au=Li%2C+Yangzi&rft.date=2024-09-30&rft.pub=BioMed+Central+Ltd&rft.issn=0949-2321&rft.volume=29&rft.issue=1&rft_id=info:doi/10.1186%2Fs40001-024-02022-z&rft.externalDBID=n%2Fa&rft.externalDocID=A810589264 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-783X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-783X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-783X&client=summon |